{"a":[{"_":"AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPD","$":{"href":"/biotech/az-rd-chief-barr-touts-internal-science-success-story-after-il-33-antibodys-stellar-showing","hreflang":"en"}}]}

RegulatoryIL-33 antibodyPositive

AI Analysis

Summary

AstraZeneca's R&D chief announced positive clinical data for the company's IL-33 antibody in COPD, which has secured FDA priority review status. The drug is positioned as a potential flagship biologic for the indication.

Outcome Details

FDA priority review granted

Importance:7/10

Sentiment:

0.75

IL-33 antibodyCOPDFDA priority reviewAstraZenecainternal development

Related Companies

$AZN

Read the original article

Published by FierceBiotech on September 8, 2026 10:18 AM

Read Original